DNMT3A and Alzheimer disease: Moreover, we found that injection of dCas9-Dnmt3a before plaque deposition effectively modulated AD pathogenesis in the AD mouse model (Fig. 4b–f); such epigenetic editing may effectively reduce the risk of AD or delay the onset of more severe symptoms before the formation of plaques and symptoms.